Dr Amit Kumar
12 posts
Dr Amit Kumar
@dramitpmc
MBBS,MD (Gen Medicine,IMS,BHU), DM , DNB(Medical Oncology,TMH,Mumbai ), ECMO, MRCP- SCE ,Medical Oncologist and Hemato Oncologist
Joined Temmuz 2012
20 Following27 Followers
Two abstracts from India relevant for LMICs for mngt of advanced head neck cancers presented side to side in #ASCO24 today.
🇮🇳 Innovation is the way to Go!!!
#GlobalOncology
@DrVijayPatil11 @oncology_bg @SuyogCancer @Bipinesh @dranuj16 @ASCOPost @TMC_Varanasi @ISMPOofficial
English
English
Happy to present our research @TataMemorial in Operated Gallbladder cancer (India centric cancer) patients at #ASCO24
Chicago, IL 🇺🇸 English
English
Now it’s time for Her 2 PET for ADCs. Drugs are evolving, so is Nuclear Medicine. @GlobOncX @KNJobanputra @drakhilkapoor1
English
@KNJobanputra Low dose ADCs unlikely to be beneficial (completely different ball game from Immunotherapy) due to very narrow therapeutic window of ADCs. @GlobOncX @KNJobanputra @drakhilkapoor1
English
Overcoming and understanding complex patterns of resistance to ADCs is vital for the success of these expensive molecules. #ASCO24
Dr Akhil Kapoor@drakhilkapoor1
Mechanism of resistance to ADCs. Next decade is likely to be ADC dominated. Understanding mechanisms and circumventing resistance is the key to success. Another point to know: <1% ADC can actually get concentrated in tumors. @GlobOncX @dramitpmc @KNJobanputra @ASCOPost
English
English
Long-term outcomes of neo-adjuvant chemotherapy on borderline resectab... sciencedirect.com/science/articl…. 10 year results with Bordeline oral cavity cancer @DrEzraCohen @VanitaNoronha @Nandinimenon18
English
Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial academic.oup.com/jnci/advance-a…
English
@VanitaNoronha @DrVijayPatil11 @Nandinimenon18 @SachinD78722095 @TataMemorial Congrats Ma'am; setting a new SOC for palliative head and neck cancer patients👌
English
In 422 pts with R/M #HNSCC, oral metronomic chemo (weekly MTX + daily celecoxib) was non-inferior (mOS 7.5 mths) to IV cisplatin (mOS 6.1 mths) and caused less toxicity. #oncoalert @DrVijayPatil11 @Nandinimenon18 @SachinD78722095 @TataMemorial authors.elsevier.com/sd/article/S22…
English
@DrVijayPatil11 A new SOC in palliative setting; hope for patients who cannot afford IO
English
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial thelancet.com/journals/langl…
English
Congrats Dr Vijay Patil and team; a milestone study on OMCT; new option for LMIC patients @VanitaNoronha @TataMemorial @JyotiBajpai01 @AnantRamaswamy @drakhilkapoor1 @dr_rajapramanik @IJMPOofficial
Dr (Prof). Vijay Patil@DrVijayPatil11
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial thelancet.com/journals/langl…
English
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial thelancet.com/journals/langl…
English